Vitamin D and Prostate Cancer

  • David Feldman
  • Roman J. Skowronski
  • Donna M. Peehl
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 354)


An analysis of the rising incidence and mortality rate of prostate cancer reveals the extraordinary importance of this disease in the world. Adenocarcinoma of the prostate is the most common cancer diagnosed in American males, reaching an estimated incidence of 32%, with 200,000 cases of newly diagnosed cancer cases expected in 1994.1 In addition, clinically inapparent prostate cancer is an extremely common finding. Over the age of 80, subclinical prostate cancer is found in approximately 60% of all men.2 Overall, it is estimated that there are 11 million men in the U.S. with lesions within their prostates that are histologically identifiable as cancer.3 Mortality from prostate cancer represents a considerable problem. It is expected that prostate cancer will account for 13% (38,000 cases) of male cancer deaths in 1994.1 This makes prostate cancer the second leading cause of cancer-related death in U.S. men after lung cancer. Mortality rates from prostate cancer appear to be on the rise. From 1970 to 1990 the age-adjusted mortality rate from prostate cancer increased approximately 7 % among U.S. caucasians. Since prostate cancer rates increase with age, as the longevity of the population increases, it is projected that prostate cancer will become the leading cause of cancer and cancer death in men. These observations demonstrate that prostate cancer is one of the major adverse factors in the health of the male population in the United States and for that matter, in the rest of the world as well.


Prostate Cancer Prostate Specific Antigen Benign Prostatic Hyperplasia Prostate Cancer Cell LNCaP Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    C.C. Boring, T.S. Squires, T. Tong, and S. Montgomery, Cancer statistics, 1994, CA Cancer J Clin. 44: 7 (1994).PubMedCrossRefGoogle Scholar
  2. 2.
    J.M. Kozlowski, and J.T. Grayhack, Carcinoma of the prostate, in: Adult and Pediatric Urology, J. Y. Gillenwater, J. T. Grayhack, S. S. Howards and J. W. Duckett, eds. Mosby Year Book, St Louis (1991).Google Scholar
  3. 3.
    H. Carter, and D. Coffey: The magnitude of the problem in the United States., in: A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer., D. Coffey Resnick,M.,Dorr,F., et al., eds. Plenum Press, New York (1988).Google Scholar
  4. 4.
    L. Cannon, D. Bishop, M. Skolnick, S. Hunt, J. Lyon, and C. Smart, Genetic epidemiology of prostate cancer in the Utah Mormon genealogy., Cancer Survey. 1: 47 (1983).Google Scholar
  5. 5.
    C. Woolf, An investigation of the familial aspects of carcinoma of the prostate, Cancer. 13: 739 (1960).PubMedCrossRefGoogle Scholar
  6. 6.
    W. Meikle, J. Smith, and D. West, Familial factors affecting prostatic cancer risk and plasma steroid levels, Prostate. 6: 121 (1985).PubMedCrossRefGoogle Scholar
  7. 7.
    J.D. McConnell, Physiologic basis of endocrine therapy for prostatic cancer, Urol Clin North Amer. 18: 1 (1991).Google Scholar
  8. 8.
    P. Ekman, and J. Brolin, Steroid receptor profile in human prostate cancer metastases as compared with primary prostatic carcinoma, Prostate. 18: 147 (1991).PubMedCrossRefGoogle Scholar
  9. 9.
    C. Huggins, R.E. Stevens, and C.V. Hodges, Studies on prostatic cancer.II. The effects of castration on advanced carcinoma of the prostate gland, Arch Surg. 43: 209 (1941).CrossRefGoogle Scholar
  10. 10.
    R.M. Wolf, S.L. Schneider, J.E. Pontes, L. Englander, J.P. Karr, G.P. Murphy, and A.A. Sandberg, Estrogen and progestin receptors in human prostatic carcinoma, Cancer. 55: 2477 (1985).PubMedCrossRefGoogle Scholar
  11. 11.
    G.G. Schwartz, and B.S. Hulka, Is Vitamin D deficiency a risk factor for prostate cancer?(Hypothesis), Anticancer Res. 10: 1307 (1990).PubMedGoogle Scholar
  12. 12.
    C.F. Garland, G.W. Comstock, F.C. Garland, K.J. Helsing, E.K. Shaw, and E.D. Gorham, Serum 25-Hydroxyvitamin D and colon cancer: Eight-year prospective study., Lancet. 2: 1176 (1989).PubMedCrossRefGoogle Scholar
  13. 13.
    C.F. Garland, F.C. Garland, and E.D. Gorham, Can colon cancer incidence and death rates be reduced with calcium and vitamin D?, Am J Clin Nutr. 54 (Suppl.1): 193 (1991).Google Scholar
  14. 14.
    C.L. Hanchette, and G.G. Schwartz, Geographic patterns of prostate cancer mortality: Evidence for a protective effect of ultraviolet radiation, Cancer. 70: 2861 (1992).PubMedCrossRefGoogle Scholar
  15. 15.
    R.J. Skowronski, D.M. Peehl, and D. Feldman, Vitamin D and prostate cancer: 1,25 Dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines, Endocrinology. 132: 1952 (1993).PubMedCrossRefGoogle Scholar
  16. 16.
    R.J. Skowronski, D.M. Peehl, and D. Feldman, Actions of vitamin D3 analogs on human prostate cancer cell lines: Comparison with 1,25-dihydroxyvitamin D3, Endocrinology 136: 20 (1995).PubMedCrossRefGoogle Scholar
  17. 17.
    D.M. Peehl, R.J. Skowronski, G.K. Leung, S.T. Wong, T.A. Stamey, and D. Feldman, Antiproliferative effects of 1,25-Dihydroxyvitamin D3 on primary cultures of human prostatic cells, Cancer Res. 54: 805 (1994).PubMedGoogle Scholar
  18. 18.
    D. Peehl, R.J. Skowronski, and D. Feldman, Role of vitamin D receptors in prostate cancer, in: Intl. Symp.“Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects, Elsevier, Amsterdam, in press (1994).Google Scholar
  19. 19.
    E.H. Corder, H.A. Guess, B.S. Hulka, G.D. Friedman, M. Sadler, R.T. Vollmer, B. Lobaugh, M.K. Drezner, J.h. Vogelman, and N. Orentreich, Vitamin D and prostate cancer: A prediagnostic study with stored sera, Cancer Epidemiology, Biomakers & Prevention. 2: 467 (1993).Google Scholar
  20. 20.
    A.W. Norman, J. Roth, and L. Orci, The vitamin D endocrine system: Steroid metabolism, hormone receptors, and biological response (calcium binding proteins)., Endocr Rev. 3: 331 (1982).PubMedCrossRefGoogle Scholar
  21. 21.
    J.W. Pike, Vitamin D3 receptors: structure and function in transcription, Ann Rev Nutr. 11: 189 (1991).CrossRefGoogle Scholar
  22. 22.
    R.M. Evans, The steroid and thyroid hormone receptor superfamily, Science. 240: 889 (1988).PubMedCrossRefGoogle Scholar
  23. 23.
    B. O’Malley, The steroid receptor superfamily: more excitement predicted for the future, Mol Endocrinol. 4: 363 (1990).PubMedCrossRefGoogle Scholar
  24. 24.
    D. Feldman, and P.J. Malloy, Hereditary 1,25 dihydroxyvitamin D resistant rickets: Molecular basis and implications for the role of 1,25(OH)2D3 in normal physiology, Mol Cell Endocrinol. 72: C57 (1990).PubMedCrossRefGoogle Scholar
  25. 25.
    G.J. Miller, G.E. Stapleton, J.A. Ferrara, M.S. Lucia, S. Pfister, T.E. Hedlund, and P. Upadhya, The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1a,25-dihydroxyvitamin D3, Cancer Res. 52: 515 (1992).PubMedGoogle Scholar
  26. 26.
    K. Burton, A study of conditions and mechanisms of the diphenyl amine colorimetric estimation of deoxyribonucleic acid, Biochem J. 62: 315 (1956).PubMedGoogle Scholar
  27. 27.
    C. Auffray, and F. Rougeon, Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA., Eur JBiochem. 107: 303 (1980).CrossRefGoogle Scholar
  28. 28.
    A.R. Baker, D.P. McDonnell, M. Hughes, T.M. Crisp, D.J. Mangelsdorf, M.R. Haussier, J.W. Pike, J. Shine, and B.W. O’Malley, Cloning and expression of full-length cDNA encoding human vitamin D receptor., Proc Natl Acad Sci USA. 85: 3294 (1988).PubMedCrossRefGoogle Scholar
  29. 29.
    Y. Ohyama, M. Noshiro, and K. Okuda, Cloning and expression of cDNA encoding 25-hydroxyvitamin D3 24-hydroxylase, FEBSLett. 278: 195 (1991).PubMedCrossRefGoogle Scholar
  30. 30.
    T.A. Stamey, H.C.B. Graves, N. Wenner, M. Ferrari, and F. Freiha, Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen, J Urol. 149: 787 (1993).PubMedGoogle Scholar
  31. 31.
    P.J. Malloy, Z. Hochberg, D. Tiosano, J.W. Pike, M.R. Hughes, and D. Feldman, The molecular basis of hereditary 1,25-dihydroxyvitamin D3 resistant rickets in seven related families, J Clin Invest. 86: 2071 (1990).PubMedCrossRefGoogle Scholar
  32. 32.
    J.W. Pike, Monoclonal antibodies to chick intestinal receptors for 1,25-dihydroxyvitamin D3, J Biol Chem. 259: 1167 (1984).PubMedGoogle Scholar
  33. 33.
    T.A. Stamey, and J.N. Kabalin, Prostate specific antigen in the diagnosis and teratment of adenocarcinoma of the prostate.I.Untreated patients, J Urol. 141: 1070 (1989).PubMedGoogle Scholar
  34. 34.
    H.-P. Schmid, J.E. McNeal, and T.A. Stamey, Observations on the doubling time of prostate cancer, Cancer. 71: 2031 (1993).PubMedCrossRefGoogle Scholar
  35. 35.
    M.A. Anzano, J.M. Smith, M.R. Uskokovic, C.W. Peer, L.T. Mullen, J.J. Letterio, M.C. Welsh, M.W. Shrader, D.1. Logsdon, C.L. Driver, C.C. Brown, A.R. Roberts, and M.B. Sporn, la,25-Dihydroxy-16ene-23yne-26,27-hexafluorocholecalciferol (Ro24–5531) a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat, Cancer Res. 54: 1653 (1994).PubMedGoogle Scholar
  36. 36.
    K.W. Colston, A.G. Mackay, S. Chander, L. Binderup, and R.C. Coombes, Novel vitamin D analogues suppress tumor growth in vivo, in: Vitamin D: Gene Regulation, Structure-Function Analysis and Clinical Application: Proceedings of the Eighth Workshop on Vitamin D, Berlin, de Gruyter, 465 (1991).Google Scholar
  37. 37.
    G. Schleicher, T.H. Privette, and W.E. Stumpf, Distribution of soltriol [1,25(OH)2-Vitamin D3] binding sites in male sex organs of the mouse: An autoradiographic study., J Histochem Cytochem. 37: 1083 (1989).PubMedCrossRefGoogle Scholar
  38. 38.
    M.R. Walters, D.L. Cuneo, and A.P. and Jamison, A possible significance of new target tissues for 1,25-dihydroxyvitamin D3, J Steroid Biochem. 19: 913 (1983).PubMedCrossRefGoogle Scholar
  39. 39.
    K. Colston, J.M. Colston, Fieldsteel, and D. Feldman, 1,25-Dihydroxyvitamin D3 receptors in human epithelial cancer cell lines, Cancer Res. 42: 856 (1982).PubMedGoogle Scholar
  40. 40.
    B.C. Osmundsen, H.F.S. Huang, M.B. Anderson, S. Christakos, and M.R. Walters, Multiple sites of action of the vitamin D endocrine system: FSH stimulation of testis 1,25-dihydroxyvitamin D3 receptors, J Steroid Biochem. 34: 339 (1989).PubMedCrossRefGoogle Scholar
  41. 41.
    H. Reichel, H.P. Koeffler, and A.W. Norman, The role of the vitamin D endocrine system in health and disease, N Engl J Med. 320: 980 (1989).PubMedCrossRefGoogle Scholar
  42. 42.
    W.E. Stumpf, M. Sar, F.A. Reid, and e. al., Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid, Science. 206: 1188 (1979).Google Scholar
  43. 43.
    E. Abe, C. Miyayra, H. Sakagami, M. Takeda, K. Konno, T. Yamazaki, S. Yoshiki, and T. Suda, Differentiation of mouse myeloid leukemia cells induced by la,25-dihydroxyvitamin D3., Proc NatlAcad Sci USA. 78: 4990 (1981).PubMedCrossRefGoogle Scholar
  44. 44.
    K.W. Colston, U. Berger, and R.C. Coombes, Possible role for vitamin D in controlling breast cancer cell proliferation, Lancet. 1:188 (1989).Google Scholar
  45. 45.
    J.A. Eisman, D.H. Barkla, and P.J. Tutton, Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3, Cancer Res. 47: 21 (1987).PubMedGoogle Scholar
  46. 46.
    K. Colston, J.M. Colston, and D. Feldman, 1,25-Dihydroxyvitamin D3 and malignant melanoma: The presence of receptors and inhibition of cell growth in culture, Endocrinology. 108: 1083 (1981).PubMedCrossRefGoogle Scholar
  47. 47.
    A. Brehier, and M. Thomassat, Human colon cell line HT-29: Characterisation of 1,25-dihydroxyvitamin D3 receptor and induction of differentiation by the hormone, J Steroid Biochem. 29: 265 (1988).PubMedCrossRefGoogle Scholar
  48. 48.
    K.D. Harper, R.V. Iozzo, and J.G. Haddad, Receptors for and bioresponses to 1,25-dihydroxyvitamin D in a human colon carcinoma cell line (HT-29), Metabolism. 38: 1062 (1989).PubMedCrossRefGoogle Scholar
  49. 49.
    X. Zhao, and D. Feldman, Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells, Endocrinology. 132: 1808 (1993).PubMedCrossRefGoogle Scholar
  50. 50.
    P. Lointier, F. Meggouh, P. Dechelotte, D. Pezet, C. Ferrier, J. Chipponi, and S. Saez, 1,25-Dihydroxyvitamin D3 receptors and human colon adenocarcinoma, BrJSurg. 78: 435 (1991).PubMedCrossRefGoogle Scholar
  51. 51.
    C.F. Garland, and F.C. Garland, Do vitamin D and sunlight reduce the likelihood of colon cancer?, Int J Epidemiol. 9: 227 (1980).PubMedCrossRefGoogle Scholar
  52. 52.
    H.A.P. Pols, J.C. Birkenhager, J.A. Foekens, and J.P.T.M. Van Leeuwen, Vitamin D: A modulator of cell proliferation and differentiation, JSteroid Biochem. 37: 873 (1990).Google Scholar
  53. 53.
    T.A. Owen, M.S. Aronow, L.M. Barone, B. Bettencourt, G.S. Stein, and J.B. Lian, Pleitropic effects of vitamin D on osteoblast gene expression are related to the proliferative and differentiated state of the bone cell phehnotype: Dependency upon basal levels of gene expression, duration of exposure, and bone matrix competency in the normal rat osteoblast cultures, Endocrinology. 128: 1496 (1991).PubMedCrossRefGoogle Scholar
  54. 54.
    E.M. Costa, H.M. Blau, and D. Feldman, 1,25-dihydroxyvitamin D3 receptors and hormonal responses in cloned human skeletal muscle cells, Endocrinology. 119: 2214 (1986).PubMedCrossRefGoogle Scholar
  55. 55.
    S. Pillai, D.D. Bikle, and P.M. Elias, 1,25-dihydroxyvitamin D production and receptor binding in human keratinocytes varies with differentiation., JBiol Chem. 263: 5390 (1988).Google Scholar
  56. 56.
    T. Suda, T. Shinki, and N. Takahashi, The role of vitamin D in bone and intestinal cell differentiation, Ann Rev Nutr. 10: 195 (1990).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • David Feldman
    • 1
  • Roman J. Skowronski
    • 1
  • Donna M. Peehl
    • 1
  1. 1.Departments of Medicine and Urology (D.M.P.)Stanford University School of MedicineStanfordUSA

Personalised recommendations